We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » False or Misleading Claims Get Rexulti and Phexxi FDA Untitled Letters
False or Misleading Claims Get Rexulti and Phexxi FDA Untitled Letters
Untitled letters sent to Otsuka Pharmaceutical and Evofem Biosciences alleging false or misleading claims that inflated the effectiveness of the products in direct-to-consumer (DTC) advertising were recently released by the FDA Office of Prescription Drug Promotion (OPDP).